A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population

Mostrar otras versiones (1)

This article has been corrected. Please see J Manag Care Spec Pharm, 2020;26(5):682 BACKGROUND: Clinical trials have shown that direct oral anticoagulants (DOACs)—including dabigatran, rivaroxaban, apixaban, and edoxaban—are at least as effective and safe as warfarin for the risk of stroke/systemic...

Descripción completa

Detalles Bibliográficos
Autores principales: Amin, Alpesh, Keshishian, Allison, Trocio, Jeffrey, Dina, Oluwaseyi, Le, Hannah, Rosenblatt, Lisa, Liu, Xianchen, Mardekian, Jack, Zhang, Qisu, Baser, Onur, Nadkarni, Anagha, Vo, Lien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398709/
https://www.ncbi.nlm.nih.gov/pubmed/32347184
http://dx.doi.org/10.18553/jmcp.2020.26.5.639

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398709/
https://www.ncbi.nlm.nih.gov/pubmed/32347184
http://dx.doi.org/10.18553/jmcp.2020.26.5.639

Ejemplares similares